Answers are grounded in this paper and cite their sources.
Retinal drug development depends on visual acuity and imaging endpoints that are slow to change and say little about mechanism. Proteomic analysis of ocular fluid, often called liquid biopsy, can now measure thousands of proteins in a few microliters of aqueous humor and infer, through integration with single-cell transcriptomic atlases, the retinal cell types from which many of them are likely to originate. Whether this capability should change how trials are designed is contested. This Perspective sets out both sides of a debate first held at the 16th Congress on Controversies in Ophthalmology. The case for holds that liquid biopsy proteomics can stratify patients by molecular state, show that a drug reaches the eye and shifts its pathway, and support earlier development decisions. The case for caution holds that no ocular fluid biomarker has been validated against clinical outcome, that the published human evidence is small and exploratory, and that sampling, cost and scale limit its use in large trials. We agree on a phase-dependent position: ocular fluid proteomics is promising as a prespecified exploratory or pharmacodynamic substudy in selected phase 0 to 2 trials where the mechanism can be read in fluid; it belongs in a prespecified substudy, not the primary analysis, in phase 3 and 4; and no surrogate endpoint claim should be made until prospective validation exists. We list the studies that would settle the question.
No takes yet. Share an insight, caveat, or question.
Almeida et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: